Vanda Pharma Can't Nix Investors' Off-Label Fraud Suit
A New York federal judge declined Wednesday to allow Vanda Pharmaceuticals Inc. or its CEO to slip a proposed securities class action alleging the company misled investors by aggressively marketing drugs...To view the full article, register now.
Already a subscriber? Click here to view full article